The industry is expected to grow significantly over the next few years as healthcare accessibility improves and insurance penetration increases
The company allocated €56 million to research and development for next-generation line solutions
The said certificate is valid for a period of 3 years and opens up the European and other markets for the company's products
The fresh capital will propel Cordance into its first-in-human clinical trial
The Unit is approved by major regulators like EMA, Europe; Health Canada, Anvisa, Brazil and TGA, Australia
Tamsulosin, an alpha-1 adrenergic receptor blocker, combined with Dutasteride, a dual 5- alpha-reductase inhibitor, is indicated for the treatment of moderate to severe symptoms of benign prostatic hyperplasia (BPH) in adult men
This facility is capable of manufacturing, packaging, testing, storage and distribution of two types of complex dosage forms
The trial targets MCAS/MCAD, an under-recognized, debilitating condition with an unknown cause and no cure
This global affiliation marks a critical step in the company’s mission to create long-term value through ethical practices, scientific innovation, and inclusive healthcare delivery
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
